Detail akcie Galapagos online

Business Summary: Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Galapagos NV revenues increased 8% to EUR216.8M. Net loss before extraordinary items totaled EUR20.4M vs. income of EUR36.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects R&D segment loss increase of 53% to EUR38.2M. Basic Earnings per Share excluding Extraordinary Items decreased from EUR0.54 to -EUR0.30.